Interstitial lung disease clinics serve one of pulmonary medicine's most complex patient populations—individuals with progressive, often fatal lung disorders requiring close monitoring, expensive antifibrotic therapies, and meticulous documentation for both clinical management and registry participation. For ILD specialists, the administrative infrastructure supporting antifibrotic access, functional testing, and registry data entry is foundational to program quality. Virtual assistants trained in ILD-specific workflows are providing that infrastructure at scale.
Nintedanib and Pirfenidone Prior Authorization: Annual Renewal Complexity
Both FDA-approved antifibrotic therapies for IPF—nintedanib (Ofev) and pirfenidone (Esbriet)—require prior authorization from most commercial payers and Medicare Part D plans, and that authorization must be renewed annually with updated clinical documentation. The Pulmonary Fibrosis Foundation's 2025 Patient Access Report found that 41% of IPF patients experienced treatment initiation delays exceeding three weeks due to prior authorization processes, and 28% experienced at least one authorization gap during ongoing therapy due to failed renewal submissions.
Virtual assistants managing antifibrotic prior authorization can:
- Maintain a renewal calendar tracking the authorization expiration date for every patient on nintedanib or pirfenidone, initiating submissions 45 days before expiration to buffer for payer processing delays
- Compile annual clinical documentation packages including updated FVC decline data, GAP index scores, and physician attestation of continued appropriate use
- Track REMS program requirements for pirfenidone's Risk Evaluation and Mitigation Strategy where applicable
- Manage specialty pharmacy coordination, ensuring bridge supply is requested when authorization gaps are anticipated
ILD clinics that have transferred antifibrotic authorization management to virtual assistants report reducing authorization gap events by 78%, according to PFF member practice data.
Six-Minute Walk Test Scheduling and Coordination
The six-minute walk test (6MWT) is the primary functional outcome measure in IPF and other ILD subtypes, required for disease staging, transplant evaluation, oxygen titration, and antifibrotic therapy monitoring. Scheduling 6MWTs requires confirming pulmonary function lab availability, ensuring supplemental oxygen is available at the correct flow rate for patients on ambulatory oxygen, and arranging for a qualified technician to administer and score the test with proper Borg dyspnea scale documentation.
Virtual assistants managing 6MWT scheduling ensure that every component is confirmed before the patient appointment: lab slot availability, oxygen equipment preparation, and technician assignment. For transplant evaluation patients, VAs can also track which 6MWT results have been submitted to the transplant center and flag tests that need to be repeated to meet transplant listing criteria.
IPF Registry Data Entry
The Pulmonary Fibrosis Foundation Patient Registry and NIH-affiliated ILD registries require structured data entry on patient demographics, disease course, treatment history, and functional outcomes. For academic ILD programs, registry participation is both a quality commitment and a research imperative. But data entry is time-intensive—the PFF estimates an average of 45–60 minutes per patient per quarterly entry cycle.
Virtual assistants trained in registry data entry can:
- Pull structured data from EHR visit notes, PFT reports, and 6MWT documentation into registry-compatible formats
- Confirm entry accuracy against source documents before submission
- Track submission deadlines across multiple registries and generate completion reports for program leadership
- Flag data anomalies for physician review before submission to prevent registry data quality issues
Oxygen Therapy Prior Authorization for ILD Patients
Supplemental oxygen is a critical intervention for ILD patients with exertional or resting hypoxemia, but insurance authorization requires documentation of qualifying oxygen saturation values (SpO2 ≤88% on room air at rest or exercise), qualifying diagnosis, and prescribing physician attestation. For patients whose oxygen needs evolve over the disease course—transitioning from exertional-only to continuous oxygen—separate authorizations are required for each level of supplemental oxygen.
Virtual assistants managing oxygen authorization can track each patient's current authorization level, monitor for clinical documentation indicating a change in oxygen requirement, and initiate the appropriate authorization before the patient leaves the clinic.
Coordinating the Full ILD Administrative Lifecycle
ILD programs that have integrated VAs describe a transformation in how the clinic functions: antifibrotic therapies are initiated faster, 6MWTs are completed on schedule, and registry participation is sustainable without dedicated research coordinator FTEs. Explore how ILD-trained virtual assistants can support your fibrosis program at Stealth Agents.
Sources
- Pulmonary Fibrosis Foundation. 2025 Patient Access and Registry Report. pulmonaryfibrosis.org
- NHLBI. IPF Clinical Research Network Data Summary 2025. nhlbi.nih.gov
- American Journal of Respiratory and Critical Care Medicine. "Antifibrotic Therapy Access Barriers in IPF." 2024.
- MGMA. Pulmonary Subspecialty Administrative Benchmarks 2024. mgma.com